Mimedx (MDXG) Intangibles (2010 - 2026)
Mimedx (MDXG) posted Intangibles of $12.1 million for Q2 2026, down 8.02% sequentially from $13.1 million in Q1 2026, and little changed YoY from $12.0 million in Q2 2025.
Mimedx (MDXG) Intangibles (2010 - 2026) Analysis & Trends
Mimedx has reported Intangibles for 17 years, with the latest figure at $12.1 million in Q2 2026.
- Quarterly Intangibles changed 0.48% year-over-year to $12.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $12.1 million (changed 0.48% YoY) and the FY2025 annual result came in at $14.2 million, up 21.78% from the prior year.
- Intangibles declined to $12.1 million in Q2 2026 per MDXG's latest filing, from $13.1 million in the prior quarter.
- Over five years, Intangibles peaked at $14.2 million in Q4 2025 and troughed at $5.0 million in Q3 2022.
- A 5-year average of $9.1 million and a median of $11.1 million in 2025 frame the typical range for Intangibles.
- The sharpest annual moves came in 2024 and 2025: Intangibles jumped 121.15% in 2024, then slipped 11.86% in 2025.
- Over 5 years, Intangibles stood at $5.9 million in 2022, then decreased by 10.17% to $5.3 million in 2023, then soared by 121.15% to $11.6 million in 2024, then gained by 21.78% to $14.2 million in 2025, then decreased by 14.63% to $12.1 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $12.1 million, $13.1 million, and $14.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | 12.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.09 Mn |
| Mar 31, 2026 | 13.14 Mn |
| Dec 31, 2025 | 14.16 Mn |
| Sep 30, 2025 | 11.15 Mn |
| Jun 30, 2025 | 12.03 Mn |
| Mar 31, 2025 | 11.06 Mn |
| Dec 31, 2024 | 11.63 Mn |
| Sep 30, 2024 | 11.20 Mn |
| Jun 30, 2024 | 12.05 Mn |
| Mar 31, 2024 | 12.55 Mn |
| Dec 31, 2023 | 5.26 Mn |
| Sep 30, 2023 | 5.40 Mn |
| Jun 30, 2023 | 5.57 Mn |
| Mar 31, 2023 | 5.71 Mn |
| Dec 31, 2022 | 5.85 Mn |
| Sep 30, 2022 | 4.99 Mn |
| Jun 30, 2022 | 5.14 Mn |
| Mar 31, 2022 | 5.27 Mn |
| Dec 31, 2021 | 5.38 Mn |
| Sep 30, 2021 | 5.62 Mn |